Publication: 3659

Publication: 3659

Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in High-Risk Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): a Subgroup Analysis of GRIFFIN (AFT-29)

DOI

URL

Google Scholar

Citation:: Blood vol 138 (Supplement 1) 2723

Meeting Instance:: ASH 2021
Year:: 2021
Type:: Abstract
Sub type:: Oral
Funding:: AFT
Endpoint:: Secondary-not-in-original
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: epub

Note:

Methodological:: No
Biospecimen:: No
SDC:: No

Parents:: None
Children:: 3854

Program:: OGC
Primary Committee:: Myeloma
Sec. Committees:

Pharmas:: JNJ
Grants:

Corr. Author:
Authors:: Larry D. Anderson Jr. Jonathan L. Kaufman Jacob Laubach Douglas W. Sborov Brandi Reeves Cesar Rodriguez Ajai Chari Rebecca Silbermann Luciano J. Costa Nitya Nathwani Nina Shah Naresh Bumma Sarah A. Holstein Caitlin Costello Andrzej Jakubowiak Tanya M. Wildes Robert Z. Orlowski Kenneth H. Shain Andrew J. Cowan Huiling Pei Annelore Cortoos Sharmila Patel Blake Bartlett Jessica Vermeulen Thomas S. Lin Peter M. Voorhees Paul G. Richardson

Networks:: CA043, CA249, CA824, FL065, LAPS-AL002, LAPS-IL057, LAPS-MA036, LAPS-NC007, LAPS-OH007, LAPS-TX011, LAPS-TX035, LAPS-UT003, NC002, NE003, NEWMEXICO, NY021, OR013

Study: AFT-29 (GRIFFIN)
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 2

Keywords: